Eli Lilly is experiencing a surge in profits due to high demand for weight loss drugs Zepbound and diabetes drugs Mounjaro.[1][2][4] Mounjaro's sales grew 110% year-over-year globally and 57% in the US to $4.1 billion, while Zepbound's US sales reached $4.2 billion, up 122% year-over-year.[4] The company forecasts revenue growth of approximately 25% and adjusted earnings per share of $34.25 for 2026, up 31% year-over-year.[2] Eli Lilly dominates the market against Novo Nordisk, which expects sales to decline by 5 to 13%.[2] The company plans to approve the oral weight loss drug orforglipron later this year.[4][6] Mounjaro activates GIP and GLP-1 receptors, reduces weight in adults with BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidity.[7] After discontinuing drugs such as Mounjaro and Zepbound, patients gain weight, for example, on average almost 15 kg per year.[10]